BioInvent International AB (publ) (STO:BINV)

Sweden flag Sweden · Delayed Price · Currency is SEK
21.60
-0.55 (-2.48%)
Mar 3, 2026, 5:29 PM CET
-22.30%
Market Cap 1.42B
Revenue (ttm) 226.50M
Net Income (ttm) -332.86M
Shares Out 65.80M
EPS (ttm) -5.06
PE Ratio n/a
Forward PE 10.16
Dividend n/a
Ex-Dividend Date n/a
Volume 61,208
Average Volume 117,936
Open 22.00
Previous Close 22.15
Day's Range 21.35 - 22.00
52-Week Range 21.35 - 41.60
Beta -0.03
RSI 24.64
Earnings Date Feb 26, 2026

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 109
Stock Exchange Nasdaq Stockholm
Ticker Symbol BINV
Full Company Profile

Financial Performance

In 2025, STO:BINV's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.

Financial Statements

News

BioInvent International AB (FRA:BIX0) Q4 2025 Earnings Call Highlights: Navigating Challenges ...

BioInvent International AB (FRA:BIX0) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives

5 days ago - GuruFocus

BioInvent International AB (publ) 2025 Q4 - Results - Earnings Call Presentation

2026-02-26. The following slide deck was published by BioInvent International AB (publ) in conjunction with their 2025 Q4 earnings call.

5 days ago - Seeking Alpha

Q4 2025 BioInvent International AB Earnings Call Transcript

Q4 2025 BioInvent International AB Earnings Call Transcript

5 days ago - GuruFocus

BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst ...

BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst Financial Challenges

4 months ago - GuruFocus

Q3 2025 BioInvent International AB Earnings Call Transcript

Q3 2025 BioInvent International AB Earnings Call Transcript

4 months ago - GuruFocus

Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, B...

1 year ago - Benzinga